

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/601,171-Conf. #4940
				Filing Date	June 23, 2003
				First Named Inventor	Gerald Walter FISCHER
				Art Unit	1645
				Examiner Name	N. Archie
Sheet	1	of	1	Attorney Docket Number	SYNI-003CN

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/NA/	C1	DeJonge et al., Clinical Trial of Safety and Efficacy of INH-A21 for the Prevention of Nosocomial Staphylococcal Bloodstream Infection in Premature Infants, <i>J. Pediatr.</i> , 151(3):232-234, 2007.	
/NA/	C2	The Encyclopedia of Molecular Biology, 1994; Ed. Sir John Kendrew	
/NA/	C3	Reider et al., Opsonic Activity of Human Ascitic Fluid, <i>Hepatology</i> , 6(3):545-546 May/June 1986	
/NA/	C4	Weisman, Antibody for the Prevention of Neonatal Nosocomial Staphylococcal Infection: A Review of the Literature, <i>Arch. Pediatr.</i> , 14 Suppl. 1:S31-S34, 2007.	

Examiner Signature	/Nina Archie/ /NAA/	Date Considered	4/8/2009 9/5/2012
-----------------------	---------------------	--------------------	-------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: December 3, 2008

Electronic Signature for Amy E. Mandragouras: /Amy E. Mandragouras/

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./